

# Chelsea C Pinnix

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9087698/chelsea-c-pinnix-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

132  
papers

1,637  
citations

23  
h-index

37  
g-index

138  
ext. papers

2,128  
ext. citations

3  
avg, IF

4.22  
L-index

#	Paper	IF	Citations
132	Implementation and Assessment of an Informal Virtual Elective for Medical Student Radiation Oncology Exploration During the COVID19 Pandemic: a Brief Report.. <i>Journal of Cancer Education</i> , <b>2022</b> , 1	1.8	
131	Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 2463-2463	2.2	
130	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. <i>Blood</i> , <b>2021</b> , 138, 4536-4536	2.2	
129	Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 3526-3526	2.2	
128	Radiomic Phenotypes of High and Low Lesion SUV Components for the Prediction of Refractory Disease in Hodgkin's Lymphoma Patients Treated with ABVD Based Therapy. <i>Blood</i> , <b>2021</b> , 138, 3996-3996 <sup>2</sup>		
127	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 648655	5.3	4
126	A call for an unbalanced force to combat racism and health disparity. <i>Lancet Haematology</i> , <b>2021</b> , 8, e173-e174	14.6	
125	Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2400-2407	1.9	1
124	Potential Implications of the New USMLE Step 1 Pass/Fail Format for Diversity Within Radiation Oncology. <i>Advances in Radiation Oncology</i> , <b>2021</b> , 6, 100524	3.3	4
123	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radiation society appropriate use criteria. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1057-1065	1.9	3
122	A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 109, 1414-1420	4	0
121	Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 560-567	4.5	4
120	Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 17	7	2
119	Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma. <i>British Journal of Radiology</i> , <b>2021</b> , 94, 20210360	3.4	0
118	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radiation Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 111, 36-44	4	1
117	Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 163, 199-208	5.3	1
116	The impact of cell-of-origin, MYC/Bcl-2 dual expression and rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1361-1369	1.9	0

115	Effect of Deep Inspiration Breath Hold on Normal Tissue Sparing With Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma. <i>Advances in Radiation Oncology</i> , <b>2020</b> , 5, 1255-1266	3.3	4
114	Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 153, 163-171	5.3	1
113	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2013935	10.4	3
112	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2442-2447	1.9	0
111	PET Guided Therapy for Early Stage Hodgkin Lymphoma: Are We Positive About a Negative Interim Scan?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 107, 12-17	4	3
110	Daily computed tomography image guidance: Dosimetric advantages outweigh low-dose radiation exposure for treatment of mediastinal lymphoma. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 152, 14-18	5.3	2
109	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. <i>Blood</i> , <b>2020</b> , 135, 2365-2374	2.2	14
108	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , <b>2020</b> , 4, 2871-2883	7.8	48
107	Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. <i>EJHaem</i> , <b>2020</b> , 1, 272-276	0.9	2
106	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 107, 909-933	4	26
105	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , <b>2020</b> , 136, 17-18	2.2	
104	Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	
103	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 22-22	2.2	
102	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , <b>2020</b> , 136, 17-18	2.2	
101	Association of Smoking with Advanced Stage and Survival Outcomes in Classic Hodgkin Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 34-35	2.2	
100	Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. <i>Blood</i> , <b>2020</b> , 136, 27-28	2.2	1
99	Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant. <i>Blood</i> , <b>2020</b> , 136, 28-29	2.2	
98	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. <i>Blood</i> , <b>2020</b> , 136, 27-28	2.2	

97	Prognostic Value of Delta Lymphocyte Index (DLI <sub>x</sub> ) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , <b>2020</b> , 136, 23-24	2.2	
96	Real Life Treatment Alterations of Frontline Therapies in Classic Hodgkin's Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 23-24	2.2	
95	High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). <i>Blood</i> , <b>2020</b> , 136, 32-33	2.2	
94	Development, implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents. <i>Brachytherapy</i> , <b>2020</b> , 19, 738-745	2.4	3
93	Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Prospective Series of 52 Patients. <i>Annals of Surgery</i> , <b>2020</b> , 275,	7.8	6
92	An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. <i>Cancer Medicine</i> , <b>2020</b> , 9, 663-670	4.8	9
91	Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT. <i>Clinical and Translational Radiation Oncology</i> , <b>2020</b> , 24, 79-82	4.6	7
90	Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2980-2984	1.9	2
89	Linguistic Biases in Letters of Recommendation for Radiation Oncology Residency Applicants from 2015 to 2019. <i>Journal of Cancer Education</i> , <b>2020</b> , 1	1.8	5
88	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 171-175	1.9	10
87	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. <i>Haematologica</i> , <b>2020</b> , 105, e355-e357	6.6	3
86	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 533-541	2	0
85	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 131, 88-92	5.3	3
84	Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , <b>2019</b> , 35, 243-246	1.4	3
83	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e465-e469	2	2
82	Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets. <i>Practical Radiation Oncology</i> , <b>2019</b> , 9, 147-152	2.8	
81	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 447-455	4	16
80	Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 381-389	2	2

79	Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2432-2440	1.9	2
78	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 244-250	2	7
77	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. <i>Scientific Reports</i> , <b>2019</b> , 9, 1322	4.9	38
76	Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 3258-3265	1.9	1
75	The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation <b>2019</b> , 59-72		0
74	Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 1609-1609	2.2	6
73	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. <i>Journal of Cardiovascular Imaging</i> , <b>2019</b> , 27, 268-279	1.3	23
72	Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E150-E153	7.1	3
71	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , <b>2019</b> , 3, 1356-1367	7.8	9
70	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e51-e61	2	7
69	Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 292-293	4.5	
68	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1602-1609	4.7	7
67	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 100, 1146-1154	4	7
66	Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2650-2659	1.9	1
65	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 100, 652-669	4	41
64	Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 545-549	4.5	26
63	Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2896-2903	1.9	8
62	Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 530-540	4	15

61	Deep-Inspiration Breath-Hold Intensity Modulated Radiation Therapy to the Mediastinum for Lymphoma Patients: Setup Uncertainties and Margins. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 100, 254-262	4	10
60	Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. <i>Blood</i> , <b>2018</b> , 131, 84-94	2.2	50
59	Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 53-58	4	24
58	Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. <i>Blood</i> , <b>2018</b> , 132, 2927-2927	2.2	2
57	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 8937-8942	4.4	1
56	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , <b>2018</b> , 2, 1334-1343	7.8	16
55	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. <i>Case Reports in Oncology</i> , <b>2018</b> , 11, 721-728	1	
54	Avoiding Topical Agents Before Daily Radiotherapy: Debunking Dogma. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1748-1750	3.4	
53	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , <b>2018</b> , 3, 639-646	3.3	5
52	Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma. <i>Advances in Radiation Oncology</i> , <b>2018</b> , 3, 372-381	3.3	5
51	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3500-3509	12.9	2
50	Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2833-2844	1.9	10
49	The Management of Lymphoma in the Setting of Pregnancy. <i>Current Hematologic Malignancy Reports</i> , <b>2017</b> , 12, 251-256	4.4	21
48	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , <b>2017</b> , 130, 472-477	2.2	45
47	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. <i>Advances in Radiation Oncology</i> , <b>2017</b> , 2, 363-369	3.3	5
46	Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. <i>Head and Neck</i> , <b>2017</b> , 39, 1095-1100	4.2	59
45	Daily CT guidance improves target coverage during definitive radiation therapy for gastric MALT lymphoma. <i>Practical Radiation Oncology</i> , <b>2017</b> , 7, e471-e478	2.8	10
44	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 403-412	4.5	41

43	Cardiac atlas development and validation for automatic segmentation of cardiac substructures. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 122, 66-71	5.3	53
42	Lymphoma and Pregnancy-Reply. <i>JAMA Oncology</i> , <b>2017</b> , 3, 567-568	13.4	1
41	A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Cancer</i> , <b>2017</b> , 123, 1363-1371	6.4	12
40	Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 488-496	4.5	8
39	Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. <i>Advances in Radiation Oncology</i> , <b>2017</b> , 2, 370-380	3.3	3
38	Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. <i>Practical Radiation Oncology</i> , <b>2017</b> , 7, e401-e408	2.8	14
37	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 97, 333-338	4	6
36	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 155-160	7.1	17
35	Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 34-8	1.9	28
34	Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1065-9	13.4	21
33	Radiation Therapy for Diffuse Large B-Cell Lymphoma: Indications, Outcomes, and Controversies. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 641-4	4	6
32	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 122-8	2	9
31	Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 575-81	1	15
30	High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience. <i>Blood</i> , <b>2016</b> , 128, 106-106	2.2	4
29	Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. <i>Blood</i> , <b>2016</b> , 128, 4208-4208	2.2	1
28	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. <i>Journal of Medical Case Reports</i> , <b>2016</b> , 10, 209	1.2	2
27	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 894-9	7.1	11
26	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , <b>2016</b> , 122, 2680-8	6.4	31

25	Small Lymphocytic Lymphoma Presenting with Hypopituitarism. <i>American Journal of Medicine</i> , <b>2016</b> , 129, e9-e10	2.4	1
24	Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 96, 110-8	4	7
23	Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2612-8	1.9	1
22	Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 96, 951-958	4	5
21	Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 113-21	4	43
20	Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 175-82	4	88
19	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1914-20	4.7	32
18	Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 122-9	4	24
17	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 664-670.e2	2	2
16	Radiation-related heart and vascular disease. <i>Future Oncology</i> , <b>2015</b> , 11, 2067-76	3.6	17
15	Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. <i>Radiation Oncology</i> , <b>2015</b> , 10, 206	4.2	1
14	Myelopathy following intrathecal chemotherapy in adults: a single institution experience. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 122, 391-8	4.8	28
13	Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. <i>Blood</i> , <b>2015</b> , 126, 1980-1980	2.2	1
12	Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery. <i>Journal of Radiosurgery and SBRT</i> , <b>2015</b> , 3, 171-178	0.4	0
11	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. <i>Blood</i> , <b>2015</b> , 126, 3865-3865	2.2	
10	Radiation Pneumonitis Risk after Bleomycin Toxicity in Hodgkin Lymphoma Patients. <i>Blood</i> , <b>2015</b> , 126, 1511-1511	2.2	
9	Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 474-9	2	17
8	Double hit lymphoma: the MD Anderson Cancer Center clinical experience. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 891-901	4.5	244



7	Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. <i>Radiation Oncology</i> , <b>2014</b> , 9, 94	4.2	73
6	Comprehensive craniospinal radiation for controlling central nervous system leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 90, 1119-25	4	15
5	Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8564-8564	2.2	
4	Double Hit Lymphoma: M.D. Anderson Experience. <i>Blood</i> , <b>2013</b> , 122, 1776-1776	2.2	3
3	Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 317-26	4	37
2	Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 1089-94	4	46
1	Gastric MALT lymphoma treated with primary radiotherapy in the setting of autoimmune disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2012</b> , 10, 815-9	7.3	2